Tardive dyskinesia: Minimizing risk and improving outcomes in schizophrenia and other disorders

American Journal of Managed Care

Volumn , Issue SUPPL., 2007, Pages 1-12

  Citrome, Leslie ^a,b   Dufresne, Robert ^c   Dyrud, Judy M ^d  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BRANCHED CHAIN AMINO ACID; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; TARVIL; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

AKATHISIA; ALCOHOLISM; ALGORITHM; DIABETES MELLITUS; DIFFERENTIAL DIAGNOSIS; DYSKINESIA; DYSTONIA; ECONOMIC ASPECT; ETHNICITY; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GENDER; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INCIDENCE; MEDICAL ETHICS; MENTAL DISEASE; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; OUTCOME ASSESSMENT; PARALYSIS; PARKINSONISM; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SUBSTANCE ABUSE; TARDIVE DYSKINESIA; TREATMENT INDICATION; TREMOR;

EID: 37849006140     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Lieberman JA, Stroup TS, McEvoy JP, et al, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
2. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Services. 2003;54:508-515.
3. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Brit J Clin Pharmacol. 2003;56:569-575.
4. Harrington C, Gregorian R, Gemmen E, et al. Access and utilization of new antidepressant and antipsychotic medications (chapter 2). US Department of Health and Human Services, 2000. Available at: http://aspe.hhs.gov/health/ Reports/Psychmedaccess/chap02.htm. Accessed June 8, 2007.
5. Slovenko R. Update on legal issues associated with tardive dyskinesia. J Clin Psychiatry. 2000;61(suppl 4):45-57.
6. Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res. 2006;81:139-143.
7. Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164:870-876.
8. Glazer WM. Managing the risk of tardive dyskinesia [interview]. Behav Health Management. 2005;25:SS1-SS6.
9. Simpson GM, Pi EH, Sramekk JJ. An update on tardive dyskinesia. Hosp Community Psychiatry. 1986;37:362-369.
10. Task Force on Late Neurological Effects of Antipsychotic Drugs. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association. Am J Psychiatry. 1980; 137:1163-1172.
11. Goetz CG. Diagnosis of tardive dyskinesia. Clin Neuropharmacol. 1983;6:101-107.
12. Dufresne RL, Wagner RL. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia. J Clin Psychiatry. 1988;49:435-438.
13. Tarsy D. History and definition of tardive dyskinesia. Clin Neuropharmacol. 1983;6:91-99.
14. Kane JM. Tardive dyskinesia circa 2006 [editorial]. Am J Psychiatry. 2006;163:1316-1318.
15. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006;21:589-598.
16. Saltz BL, Robinson DG, Woerner MG. Recognizing and managing antipsychotic drug treatment side effects in the elderly. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 2):14-19.
17. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
18. Jeste DV, Wyatt RJ. Changing epidemiology of tardive dyskinesia: an overview. Am J Psychiatry. 1981;138:297-309.
19. Kane JM, Woerner M, Weinhold P, Kinon B, Lieberman J, Wegner J. Epidemiology of tardive dyskinesia. Clin Neuropharmacol. 1983;6: 109-115.
20. Cummings JL, Wirshing WC. Recognition and differential diagnosis of tardive dyskinesia. Int J Psychiatry Med. 1989;19:133-144.
21. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry. 2000;61(suppl 4):21-26.
22. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry. 1988;39:1172-1177.
23. Klawans HL, Goetz CG, Perlik S. Tardive dyskinesia: review and update. Am J Psychiatry. 1980;137:900-908.
24. Van Harten PN, Hoek HW, Matroos GE, van Os J. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curacao Extrapyramidal Syndromes Study V. J Clin Psychiatry. 2006;67:1920-1927.
25. Germer CK, Seraydarian L, McBrearty JF. Training hospital clinicians to diagnose tardive dyskinesia. Hosp Community Psychiatry. 1984; 35:769-783.
26. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry. 2000;61(suppl 4):39-44.
27. Shapleske J, Mickay A, Mckenna PJ. Successful treatment of tardive dystonia with clozapine and clonazepam. Br J Psychiatry. 1996;168:516-518.
28. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;47:445-451.
29. Suzuki T, Uchida H, Watanae K, Kashima H. Treating a schizophrenic patient with severe tardive dystonia without antipsychotics. A case report. Prog Neuropsychopharm Biol Psychiatry. 2007. Epub ahead of print.
30. Smith JM, Baldessarini RJ. Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry. 1980;37:1368-1373.
31. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry. 2000;61(suppl 4):27-32.
32. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull. 1984;20:39-40.
33. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155:1521-1528.
34. Fenton WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry. 2000;61(suppl 4):10-14.
35. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry. 2007;20:131-137.
36. Wolf ME, Mosnaim AD. Identifying subtypes of tardive dyskinesia. Hosp Community Psychiatry. 1984;35:822-830.
37. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50:541-547.
38. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
39. Nasrallah HA. Tardive dyskinesia. NAMI National Alliance on Mental Illness. 2003. Available at: http://www.nami.org/Content/ContentGroups/ Helpline1/Tardive_Dyskinesia.htm. Accessed March 19, 2007.
40. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;61(suppl4):5-9.
41. Caroff SN, Walker P, Campbell C, Lorry A, et al. Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. J Clin Psychiatry. 2007;68:410-415.
42. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry. 2000;61(suppl 4):15-20.
43. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995;52:756-765.
44. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80:33-43.
45. Margolese HC. Psychopharmacology for the clinician. Management of conventional antipsychotic-induced tardive dyskinesia. Rev Psychiatr Neurosci. 2007;32:72.
46. Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the Motor Disorders Clinic at the Maryland Psychiatric Research Center. J Clin Psychopharmacol. 2004;24:592-598.
47. Keck PE, McElroy SL, Strakowski SM, Soutullo CA. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia. J Clin Psychiatry. 2000;61(suppl 4):33-38.
48. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry. 1993; 50:723-733.
49. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160:1117-1124.
50. Brasic JR. Tardive dyskinesia. Emedicine from WebMD. March 12, 2007 Available at: http://www.emedicine.com/neuro/topic362.htm. Accessed March 19, 2007.
51. Ganzini L, Heintz RT, Hoffman WF, Casey DE. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry. 1991;48:259-263.
52. Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ. Diabetes and development of tardive dyskinesia. Am J Psychiatry. 1993;150:966-968.
53. Schultz SK, Arndt S, Ho BC, Oliver SE, Andreasen NC. Impaired glucose tolerance and abnormal movements in patients with schizophrenia. Am J Psychiatry. 1999;156:640-642.
54. Caligiuri MP, Jeste DV. Association of diabetes with dyskinesia in older psychosis patients. Psychopharmacology (Berl). 2004;176: 281-286.
55. Levy E, Margolese HC, Annable L, Chouinard G. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use. Can J Psychiatry. 2004;49:398-402.
56. WebRef.org. Pack year. Iverson Software Co. Available at: http://www.webref.org/cancer/p/pack_year.htm. Accessed May 23, 2007.
57. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai Conference on the Pharmacotherapy of Schizophrenia. Schizophr Bull. 2002;28:5-16.
58. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry. 2006; 163:1438-1440.
59. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry. 2000;61(suppl 3):16-21.
60. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry. 2003;53:1142-1145.
61. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503-510.
62. Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM. Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry. 1994;55(suppl B):102-106.
63. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand. 1999;99:160-170.
64. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50:703-714.
65. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc. 1999;47:716-719.
66. Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry. 2000;15:506-514.
67. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-1155.
68. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry. 1999;174:23-30.
69. Jeste DV, Glazer WM, Morgenstern H, Pultz JA, Yeung PP. Rarity of tardive dyskinesia with quetiapine treatment of psychotic disorders in the elderly. Presented at: the 38th Annual Meeting of the American College of Neuropsychopharmacology; December 12-16, 1999; Acapulco, Mexico. [Scientific Book of Abstracts, p 142.]
70. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol. 2000;15:13-22.
71. Arato M, O'Connor R, Meltzer HY. A 1-year, double blind placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207-215.
72. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry. 2004; 28:985-996.
73. Chapter 11: antipsychotic agents. In: Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 2nd ed. New York, NY: Cambridge University Press; 2001:401-458.
74. De Leon J. The effect of atypical versus typical antipsychotics on tardive dyskinesia. A naturalistic study. Eur Arch Psychiatry Clin Neurosci. 2006;257:169-172.
75. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.
76. Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53:1374-1379.
77. Munetz MR, Schulz SC. Screening for tardive dyskinesia. J Clin Psychiatry. 1986;47:75-77.
78. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. 2004;65:92-96.
79. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry. 1982;39:473-481.
80. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry. 1982;39:486-487.
81. Davis JM, Schyve PM, Pavkovic I. Clinical and legal issues in neuroleptic use. Clin Neuropsychopharmacol. 1983;6:117-128.
82. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull. 1997;23:583-609.
83. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol. 2007;27:159-169.
84. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156:1279-1281.
85. Tammenmaa IA, Sailas E, McGrath JJ, Soares-Weiser K, Wahlbeck K. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:1099-1107.
86. Hardoy MC, Carta MG, Carpiniello G, et al. Gabapentin in antipsychotic induced-tardive dyskinesia: results of 1-year follow-up. J Affect Dis. 2003;75:125-130.
87. Wettstein RM, Appelbaum PS. Legal liability for tardive dyskinesia. Hosp Community Psychiatry. 1984;35:992-994.
88. Davis JM, Marder SR, Taminga CA. Switch or stay? [editorial] Am J Psychiatry. 2006;163:2032-2033.
89. Munetz MR. Overcoming resistance to talking to patients about tardive dyskinesia. Hosp Community Psychiatry. 1985;36:283-287.